Gain Therapeutics (GANX) Cash from Operations (2020 - 2026)

Gain Therapeutics has reported Cash from Operations for 7 years, with the latest figure at -$4.7 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 8.22% year-over-year to -$4.7 million in Q2 2026; TTM through Jun 2026 was -$19.0 million, a 2.72% decrease from a year earlier, with the FY2025 full-year figure at -$18.5 million, up 2.16% from the prior year.
• Cash from Operations was -$4.7 million for Q2 2026 at Gain Therapeutics, up from -$4.7 million in the prior quarter.
• The five-year high for Cash from Operations was -$2.4 million in Q1 2022, with the low at -$6.1 million in Q3 2024.
• Average Cash from Operations over 5 years is -$4.5 million, with a median of -$4.6 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations tumbled 72.32% in 2023, then jumped 38.97% in 2024.
• Over 5 years, Cash from Operations stood at -$3.9 million in 2022, then sank by 44.97% to -$5.7 million in 2023, then surged by 38.97% to -$3.5 million in 2024, then slumped by 33.69% to -$4.6 million in 2025, then slipped by 1.33% to -$4.7 million in 2026.
• The last three Cash from Operations figures came in at -$4.7 million (Q2 2026), -$4.7 million (Q1 2026), and -$4.6 million (Q4 2025), per Business Quant data.